Biopharma Could Provide a Haven for Investment as Middle East Conflict Roils Global Markets

Biotech, in particular companies that are pre-commercial with a longer-duration risk profile, could be great investments as Operation Epic Fury rolls on, according to a Truist Securities analysis.